(Barcelona, October 21, 2019) The results of a large, randomised, double-blind, placebo-controlled study have confirmed that faecal microbiota transplantation (FMT) using a single ‘super-donor’ is an effective and well tolerated treatment for irritable bowel syndrome (IBS), producing high rates of clinical response and marked symptom improvements. The study reported today, which involved a large cohort of patients with various subtypes of IBS, used several enhanced methodologies, and highlighted the importance of donor selection for optimising the effectiveness of FMT as a treatment for IBS.
Speaking at UEG Week Barcelona 2019, lead investigator, Professor Magdy El-Salhy from Haukeland University Hospital in Bergen, Norway, explained: “Microbiota dysbiosis is thought to play an important role in the pathophysiology of IBS, however, previous studies investigating FMT in this condition have produced conflicting results.
“We set out to optimise our chances of treatment success by selecting a single, well-defined donor* who fulfilled European guidelines for FMT donors, and who had a favourable faecal microbial profile.”
The study randomized 164 individuals with IBS and moderate-to-severe IBS symptoms (Irritable Bowel Syndrome Severity Scoring System [IBS-SSS] ≥175) to receive either placebo (a solution containing their own faeces), a 30 g donor transplant solution, or a 60 g transplant solution. Unlike in previous studies, the transplant material had been stored frozen (–80 °C/–112 °F), and was administered after thawing into the proximal duodenum via gastroscope – obviating the need for bowel preparation prior to transplantation and making it easier to perform in clinical practice. The primary efficacy endpoint of the study was the percentage of patients who achieved a ≥50-point reduction in IBS-SSS at 3 months after FMT (response to treatment).
According to Prof. El-Salhy, a response to FMT treatment was observed in 23.6% of individuals who received placebo, 76.9% of individuals who received a 30 g transplant, and 89.1% of individuals who received a 60 g transplant. Clinically significant symptom improvement [a ≥175-point reduction in IBS-SSS] occurred in 5.5%, 35.2%, and 47.3% of individuals in the placebo, FMT 30 g and FMT 60 g treatment groups, respectively. Significant improvements in fatigue (Fatigue Assessment Scale) and quality of life (IBS-Quality of Life instrument) were also observed in the FMT treatment groups compared with the placebo group. An analysis of faecal bacterial profiles showed changes in the abundance of different bacteria in the two FMT groups, but not in the control group.
“Adverse events after FMT occurred in about 20% of patients and were mild and self-limiting gastrointestinal symptoms such as abdominal pain, diarrhoea or constipation,” said Prof. El-Salhy. “These occurred intermittently in the first 2 days following FMT.”
Prof El-Salhy and colleagues believe this study confirms that FMT is an effective treatment for IBS, but stress the importance of using a super-donor to achieve treatment success. “We got lucky when we found our donor after screening several other candidates, and we hope the selection criteria we used will help other groups find similar individuals,” noted Prof. El-Salhy. “The use of frozen faeces eliminates the logistical problems associated with FMT involving fresh faeces, making it possible to establish bio-banks for the routine use of FMT in clinical practice.”
Notes to Editors
*The ‘super-donor’ was an athletic Caucasian male aged 36 years. He was a healthy, non-smoker, with a normal BMI, who trained five times per week. He had been born via vaginal delivery and breast fed; he was not taking any regular medications, had only received three courses of antibiotics during his lifetime, and regularly took dietary supplements rich in proteins, vitamins, fibre, and minerals.
For further information, or to arrange an interview with Professor Magdy El-Salhy, please contact Luke Paskins on +44 (0)1444 811099 or +44 (0) 7732 499170 or by email email@example.com
We kindly ask that a reference to UEG Week 2019 is included when communicating any information within this press release.
About Professor Magdy El-Salhy
Professor Magdy El-Salhy is a Professor of Gastroenterology and Hepatology at Bergen University, and consultant gastroenterologist at Stord Hospital, Norway
About UEG Week
UEG Week is the largest and most prestigious gastroenterology meeting in Europe and has developed into a global congress. It attracts over 14,000 participants each year, from more than 120 countries, and numbers are steadily rising. UEG Week provides a forum for basic and clinical scientists from across the globe to present their latest research in digestive and liver diseases, and also features a two-day postgraduate course that brings together top lecturers in their fields for a weekend of interactive learning.
UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European medical specialist and national societies focusing on digestive health.
Our member societies represent more than 30,000 specialists from every field of gastroenterology. Together, we provide services for all healthcare professionals and researchers, in the broad area of digestive health. The role of UEG is to take concerted efforts to learn more about digestive disease by prevention, research, diagnosis, cure and raising awareness of their importance.
To advance the standards of gastroenterological care and knowledge across the world and to reduce the burden of digestive diseases, UEG offers numerous activities and initiatives, including:
- UEG Week, the biggest congress of its kind in Europe, and one of the two largest in the world
- UEG Education, the universal source of knowledge in gastroenterology, providing online and classroom courses, a huge online library and delivering the latest GI news, fostering debate and discussion
- Activity Grants, promoting and funding educational projects in the field of digestive health to advance and harmonise the training and continuing education of professionals
- UEG Journal, covering translational and clinical studies from all areas of gastroenterology
- Public Affairs, promoting research, prevention, early diagnosis and treatment of digestive diseases, and helping develop an effective health policy for Europe
- Quality of Care, European-based and English clinical practice guidelines, clinical standards, consensus, position papers and standard protocols in the field of digestive health, are available in the repository.
Find out more about UEG’s work by visiting www.ueg.eu or contact:
Luke Paskins on +44 (0)1444 811099 or firstname.lastname@example.org
- El-Salhy M, Haltebakk JG, Gilja OH, et al. Effects of faecal microbiota transplantation in patients with irritable bowel syndrome (IBS): a randomised, double-blind placebo-controlled study. Presented at UEG Week October 21, 2019.
- Enck P, Mazurak N. Dysbiosis in functional bowel disorders. Ann Nutr Metab. 2018;72(4):296-306.
- Johnsen PH, Hilpusch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3(1): 17-24.
- Halkjaer SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107-15.